[注册][↗ 积极进展][MNC]礼来Jaypirca（pirtobrutinib）获FDA扩展适应症，用于部分未经治疗的CLL/SLL患者

礼来宣布美国FDA批准Jaypirca（pirtobrutinib）新增适应症，用于治疗无已知17p缺失的既往未经治疗的成人慢性淋巴细胞白血病或小淋巴细胞淋巴瘤（CLL/SLL），可作为一线治疗。 公司：Eli Lilly and Company 相关资产：Jaypirca (pirtobrutinib) 适应症：previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) without 17p deletion 阶段：FDA expanded indication approval (first-line treatment) 融资性质：不适用 来源：BioSpace · 新闻稿（https://www.biospace.com/press-releases/lillys-jaypirca-pirtobrutinib-the-first-and-only-approved-non-covalent-btk-inhibitor-receives-expanded-indication-from-u-s-fda-for-certain-patients-with-previously-untreated-cll-sll）